A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy

NCT03754764 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T ACI

Interventions

BIOLOGICAL: Specificity CD38 CAR-T Cells

Sponsor

Chinese PLA General Hospital